|
May 2
|
Kazia concludes first stage of Phase I advanced cancer treatment trial
|
|
May 1
|
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS
|
|
Mar 24
|
11 Best ASX Stocks To Buy Now
|
|
Mar 21
|
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
|
|
Mar 13
|
Kazia announces presentation of new data at AACR Annual Meeting
|
|
Dec 5
|
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
|
|
Dec 1
|
Kazia Therapeutics Announces $2 Million Registered Direct Offering
|
|
Nov 29
|
KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY
|
|
Jul 4
|
Insider Stock Buying Reaches AU$1.1m On Kazia Therapeutics
|
|
May 25
|
KAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOT
|